Key Points The giant pharmacy chain has reduced its guidance multiple times this year. Medical expenses are rising, and the company faces more competition from Amazon. CVS has a new CEO, who's been holding off for now on providing guidance for 2025. Motley Fool Issues Rare “All In” Buy Alert
David Jagielski is a writer for The Motley Fool and BAYSTREET.CA MEDIA CORP. His articles cover a wide range of investment topics, including stock analysis, market trends, and investment strategies. David's work has been featured in reputable publications such as USA TODAY, Yahoo Finance, and Nasdaq.